Cardiology Containment Regulation Research 
The Pharma Data
OCTOBER 14, 2020
Michael Felker, MD, MHS, FACC, FAHA, FHFSA is Professor of Medicine with tenure in the Division of Cardiology at Duke University School of Medicine. He is Director of Cardiovascular Research at the Duke Clinical Research Institute and Vice-Chief for Clinical Research in the Division of Cardiology. Source link.
The Pharma Data
DECEMBER 12, 2020
More recently, AstraZeneca has increased its efforts in immunology research and the development of medicines for immune-mediated diseases. AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
The Pharma Data
NOVEMBER 4, 2020
Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on hematology, nephrology, neurology, metabolic disorders, cardiology, ophthalmology and acute care. This press release and further information about Alexion can be found at: www.alexion.com.
The Pharma Data
AUGUST 30, 2021
Results were presented at the ESC Congress 2021, organized by the European Society of Cardiology (ESC). This media update contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. reduction in LDL-C from baseline to Day 510 compared with placebo ( P < 0001) 1.
The Pharma Data
AUGUST 29, 2020
Presented at the ESC Congress 2020, the annual meeting of the European Society of Cardiology, the analysis evaluated the efficacy and tolerability of inclisiran on top of a maximally tolerated dose of statins, in two studies of more than 2,300 patients (of which 1,164 were on inclisiran) from the Phase III trials.
The Pharma Data
JANUARY 12, 2021
Alexion focuses its research efforts on novel molecules and targets in the complement cascade and its development efforts on the core therapeutic areas of hematology, nephrology, neurology, metabolic disorders, cardiology and ophthalmology. Securities Act of 1933, as amended. Forward Looking Statements.
XTalks
AUGUST 2, 2023
We delve into the driving forces behind their successes and shed light on the groundbreaking research that has earned them a place among the elite in the pharmaceutical arena. It contains the antiviral medications nirmatrelvir and ritonavir. Pfizer’s total global revenue from Paxlovid was $18.93 billion in 2022. and $16,382.51
Expert insights. Personalized for you.
40 
Let's personalize your content